<DOC>
	<DOC>NCT02060721</DOC>
	<brief_summary>Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)</brief_summary>
	<brief_title>Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Written informed consent Subject with CTEPH having completed the doubleblind (DB) AC055E201/ MERIT1 study as scheduled (i.e., who remained in the DB study up to Week 24). Females of childbearing potential must have a negative pretreatment serum pregnancy test, be advised on appropriate methods of contraception, and agree to use 2 reliable methods of contraception. Permanent discontinuation of DB study treatment due to an hepatic adverse event or liver aminotransferase abnormalities. Any known factor (e.g., drug or substance abuse) or disease (e.g., unstable psychiatric illness) that, in the opinion of the investigator, may interfere with treatment compliance or interpretation of the results, or that may influence the ability to comply with any of the study requirements.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic thromboembolic pulmonary hypertension (CTEPH)</keyword>
</DOC>